期刊文献+

吉西他滨联合长春瑞滨二线治疗晚期乳腺癌疗效观察 被引量:2

下载PDF
导出
摘要 目的观察吉西他滨联合长春瑞滨(GN方案)治疗晚期乳腺癌的疗效与安全性。方法对26例经病理和免疫组化证实的接受蒽环类及紫杉类等化疗后复发和转移的晚期乳腺癌患者进行吉西他滨联合长春瑞滨方案治疗:吉西他滨1000 mg/m2静滴第1,8天;长春瑞滨25 mg/m2,静滴第1,8天。21 d为1个周期。结果 26例均可评价疗效,完全缓解1例(4%),部分缓解11例(42%),病情稳定9例(35%),病情进展5例(19%),客观有效率为46%;中位疾病进展时间7个月,中位生存期21个月,1 a生存率为70%,3 a生存率为31%。毒副反应主要为Ⅰ~Ⅱ度骨髓抑制、静脉炎、胃肠道反应等。结论吉西他滨联合长春瑞滨二线治疗晚期乳腺癌疗效显著,毒副作用轻微,患者可以耐受。
出处 《现代中西医结合杂志》 CAS 2013年第15期1671-1672,共2页 Modern Journal of Integrated Traditional Chinese and Western Medicine
  • 相关文献

参考文献7

  • 1龚新雷,秦叔逵,王琳,陈映霞,钱军,何泽明,华海清.吉西他滨为主的方案治疗难治性乳腺癌的临床研究[J].临床肿瘤学杂志,2009,14(9):812-815. 被引量:4
  • 2王晓红,任洪军.长春瑞滨或吉西他滨联合顺铂治疗耐药的晚期乳腺癌[J].临床肿瘤学杂志,2008,13(3):260-262. 被引量:5
  • 3Fuentes H, Galderillo G,Alexander F, et al. Phase Ⅱ study of gemc- itabine plus cisplatin in metastatic breast cancer [ J ]. Anticancer Drugs, 2006,17 ( 5 ) : 565 - 570.
  • 4胡定学,雷妍玮,陈容艳,张丽.吉西他滨联合顺铂治疗晚期乳腺癌临床疗效观察[J].中国肿瘤临床与康复,2008,15(6):546-548. 被引量:3
  • 5Zelek L, Barthier S, Riofrio M, et al. Weekly vinorelbine is an effec- tive palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma [ J ]. Cancer ,2001,92 (9) :2267 - 2272.
  • 6Stathopoulos GP,Rigatos SK, Pergantas N,et al. Phase U trial of bi- weekly administration of vinorelbine and gemcitabine in pre-treated advanced breast cancer[J]. J Clin Oncol,2002,20(1) :37 -41.
  • 7Sanal SM,Gokmen E, Karabulut B, et al. Gemcitabine and vinorel- bine combination in patients with metastatic breast cancer [ J ]. Breast J.2002,8(3) :171 -176.

二级参考文献17

  • 1库建伟,潘瑞华,时沛,朱琳,暴宛英.吉西他滨联合顺铂治疗复发进展期乳腺癌疗效观察[J].中国肿瘤临床与康复,2006,13(3):234-235. 被引量:2
  • 2谢国明,李海霞.吉西他滨联合顺铂对蒽环类及紫杉类耐药的晚期乳腺癌的治疗[J].中国肿瘤,2007,16(5):382-383. 被引量:13
  • 3徐兵河.蒽环类耐药性乳腺癌的治疗策略[J].中华肿瘤杂志,2007,29(4):241-244. 被引量:85
  • 4Barton BM. Gemcitabine a pharmacologic and clinical overview [J]. Cancer,1999,22(2) :176.
  • 5Boudewijn JM, Breakhuis GA, Jan BV. Predincial in viro activity gemcitabine against human head and neek cancer [ J ]. Cancer Res,1991,51 ( 1 ) :211-214.
  • 6Galvez CA, Calmarini F, Curie M. Monthly cisplatin ( C ) and gemcitabine(G) as second-line chemotherapy for patients with advanced breast cancer [ J ]. Breast Cancer Res Treat,2000,64 ( 1 ) : 81-85.
  • 7Nagourney RA,Link JS,Blltzer JB, et al. Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients [ J ]. J Clin 0neol,2000,18 ( 11 ) :2245-2249.
  • 8Elsaid AA, Elkerm Y, EI-Shami K. Trastuzumab plus gemcitabine and cisplatin chemotherapy for HER2/neu-overexpressing breast cancer with visceral metastasis[J]. Journal of Clinical Oncology, 2008, 26 (Suppl 19):1109.
  • 9Albain KS, Nag S, Calderillo-Ruiz G, et al. Global phase Ⅲ study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC) : First report of overall survival[ J]. Journal of Clinical Oncology, 2004, 22(Suppl 14) : 510.
  • 10Freier W, Stemmler HJ, Tessen H, et al. Randomised trial comparing gemcitabine plus vinorelbine (Gem/Vin), gemcitabine plus cisplatin (Gem/Cis), and gemcitabine plus capecitabine (Gem/Cap) in pretreated metastatic breast cancer (MBC)[ J]. Journal of Clinical Oncology, 2008, 26 (Suppl 19):1054.

共引文献9

同被引文献9

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部